As scrutiny into drug prices intensifies, Lilly launches half price Humalog; BioXcel, Nektar expand collab to include Bavencio in combo pancreatic cancer therapy
→ Bipartisan furor against drug prices in the United States is having a growing impact on pharmaceutical company decisions. Following Amgen $AMGN and partners Regeneron $REGN and Sanofi $SNY move to slash the price of their respective PCSK9 cholesterol drugs by 60%, Lilly $LLY on Monday made its own pledge: to offer a half-price generic of its popular insulin Humalog (which generated nearly $3 billion in 2018 sales), at a time when anecdotal reports of US diabetics rationing and in certain cases foregoing insulin are doing the rounds.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.